Soricimed Biopharma

Given SOR-C13's positive safety profile, its potential to treat pancreatic cancer and the speed at which recruitment occurred prior to COVID, our investigator-initiated trial has been selected to resume at MD Anderson Cancer Center. #oncology #pancreaticcancer #clinicaltrials #pharmaceuticals

First cohort of investigator-initiated trial, focused on late-stage pancreatic patients, showed that SOR-C13 is safe and well-tolerated.

Soricimed is developing the next generation of PDCs for cancer treatment by linking cytotoxic payloads to its proprietary TRPV6-targeting peptides.

We are pleased to participate in the BioTuesdays Pre-JPM Virtual Conference Tuesday December 10th, 1:30pm EST. To hear our Company update live or archived, register here.

Soricimed to present a business update at the first annual BioTuesday virtual conference.

Journal of Cancer Therapy identifies TRPV6 as a promising drug target in a number of cancers including breast, ovarian, prostate and pancreatic cancer.

Watch this BioTuesday video of our primary focus area, targeted drug candidates for the treatment of solid-tumor cancers

Soricimed featured in BioTuesdays

Chief Scientific Officer, Professor Jack Stewart discusses focus on ovarian, prostate and pancreatic cancers.

Soricimed today announced that MD Anderson Cancer Center has completed enrolment and begun dosing the first cohort of three late-stage pancreatic cancer patients.

Professor Jack Stewart, Chief Scientific Officer, explains the mechanism of action of Soricimed's lead drug candidate, SOR-C13.

Soricimed is partnering with UK-based IAG, a company with unique expertise in medical imaging and AI-based image analytics to predict patient treatment response in a Phase 1b investigator-initiated trial of late-stage pancreatic cancer patients

Chief Scientific Officer, Professor Jack Stewart, provides background on the investigator initiated clinical trial of SOR-C13 in late-stage pancreatic cancer.